

PET imaging of zirconium-89 labelled cetuximab

Citation for published version (APA):

van Loon, J., Even, A. J. G., Aerts, H. J. W. L., Ollers, M., Hoebbers, F., van Elmpt, W., Dubois, L., Dingemans, A-M. C., Lalisang, R. I., Kempers, P., Brans, B., Winnepenninckx, V., Speel, E-J., Thunnissen, E., Smits, K. M., Boellaard, R., Vugts, D. J., De Ruyscher, D., & Lambin, P. (2017). PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer. *Radiotherapy and Oncology*, 122(2), 267-273. <https://doi.org/10.1016/j.radonc.2016.11.020>

Document status and date:

Published: 01/02/2017

DOI:

[10.1016/j.radonc.2016.11.020](https://doi.org/10.1016/j.radonc.2016.11.020)

Document Version:

Publisher's PDF, also known as Version of record

Document license:

Taverne

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:


www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.



Phase I trial

PET imaging of zirconium-89 labelled cetuximab: A phase I trial in patients with head and neck and lung cancer



Judith van Loon^{a,1,*}, Aniek J.G. Even^{a,1}, Hugo J.W.L. Aerts^{a,b}, Michel Öllers^a, Frank Hoebers^a, Wouter van Elmpt^a, Ludwig Dubois^a, Anne-Marie C. Dingemans^c, Roy I. Lalisang^d, Pascal Kempers^e, Boudewijn Brans^e, Véronique Winnepeninckx^f, Ernst-Jan Speel^f, Eric Thunnissen^g, Kim M. Smits^a, Ronald Boellaard^h, Danielle J. Vugts^h, Dirk De Ruyscher^{a,i}, Philippe Lambin^a

^a Department of Radiation Oncology (MAASTRO), GROW – School for Oncology and Developmental Biology, Maastricht University Medical Centre, The Netherlands; ^b Departments of Radiation Oncology and Radiology, Dana-Farber Cancer Institute, Brigham and Women's Hospital, Harvard Medical School, Boston, USA; ^c Department of Pulmonology; ^d Department of Medical Oncology; ^e Department of Nuclear Medicine; ^f Department of Pathology, Maastricht University Medical Centre; ^g Department of Pathology; ^h Department of Radiology and Nuclear Medicine, VU University Medical Centre, Amsterdam, The Netherlands; and ⁱ Department of Radiation Oncology, University Hospital Leuven, KU Leuven, Belgium

ARTICLE INFO

Article history:

Received 3 June 2016

Received in revised form 18 November 2016

Accepted 26 November 2016

Available online 21 December 2016

Keywords:

⁸⁹Zr-cetuximab

EGFR

Immuno-PET

Phase I trial

ABSTRACT

Background and purpose: PET imaging of cetuximab uptake may help selecting cancer patients with the highest chance of benefit. The aim of this phase I trial was to determine the safety of the tracer ⁸⁹Zr-cetuximab and to assess tumour uptake.

Methods: Two dose schedules were used; two consecutive doses of 60 MBq ⁸⁹Zr-cetuximab or a single dose of 120 MBq, both preceded by 400 mg/m² of unlabelled cetuximab. Toxicity (CTCAE 3.0) was scored twice weekly. PET-CT scans were acquired on days 4, 5 and 6 (step 1) or 5, 6, 7 (step 2). Because tumour uptake could not be assessed satisfactorily, a third step was added including EGFR overexpressing tumours.

Results: Nine patients were included (6 NSCLC; 3 HNC). No additional toxicity was associated with administration of ⁸⁹Zr-cetuximab compared to standard cetuximab. A tumour to blood ratio (TBR) > 1 was observed in all but one patient, with a maximum of 4.56. TBR was not different between dose schedules. There was a trend for higher TBR at intervals > 5 days after injection.

Conclusions: Both presented ⁸⁹Zr-cetuximab administration schedules are safe. The recommended dose for future trials is 60 MBq, with a minimum time interval for scanning of 6 days.

© 2016 Elsevier Ireland Ltd. All rights reserved. Radiotherapy and Oncology 122 (2017) 267–273

Monoclonal antibodies are increasingly used in anticancer treatment to specifically target receptors at the surface of tumour cells, either as a monotherapy or in combination with radiotherapy or chemotherapy. Cetuximab is such a monoclonal antibody that specifically blocks the epidermal growth factor receptor (EGFR) which is over-expressed in many human malignancies [1,2]. EGFR activation and overexpression appear to be important tumour cell mechanisms in the development of resistance to radiation and chemotherapy, resulting in decreased rates of local tumour control and survival [3].

A randomized phase III trial in head and neck cancer showed improved survival of adding cetuximab to radiotherapy [4]. In contrast, cetuximab combined with radiotherapy failed to show any

benefit over chemoradiotherapy [5], moreover, the addition of cetuximab to chemoradiotherapy did not show benefit in head and neck cancer [6] or non-small cell lung cancer [7,8]. Selection of patients with the highest chance of benefit from cetuximab treatment is of obvious relevance, also in view of its high costs. The mechanisms underlying clinical response or resistance to treatment against EGFR with cetuximab combined with radiotherapy are, however, largely unknown [9,10].

Non-invasive visualization and quantification of tumour uptake of cetuximab may contribute significantly to the selection of patients and determination of the needed dosage [11]; several methods using nuclear imaging have been proposed [12,13].

As the biologic half-life of cetuximab in blood is 65–95 h [14], a radioactive tracer with a long half-life is needed to visualize its uptake. Zirconium-89 (⁸⁹Zr), with a half-life of approximately 78 h, is an example of such a positron emission tomography (PET) tracer that can successfully be labelled to cetuximab and has shown promising results in animal models [15–17]. In a

* Corresponding author at: MAASTRO Clinic, Dr. Tanslaan 12, 6229 ET Maastricht, The Netherlands.

E-mail address: Judith.vanloon@maastro.nl (J. van Loon).

¹ Equally contributing.

preclinical study, uptake of ⁸⁹Zr-cetuximab was demonstrated only in EGFR-positive tumours. However, it was shown that ⁸⁹Zr-cetuximab uptake did not correlate with EGFR expression levels, implying that pharmacokinetic and -dynamic factors influence the cetuximab accumulation in tumours [16].

Here, we report the results of a phase I study with primary aim determining the safety of zirconium-89 labelled cetuximab, with tumour ⁸⁹Zr-cetuximab uptake as a secondary end point. Furthermore, we aimed to get an indication of the optimal radioactivity dose and imaging time point to direct future phase II studies.

Methods

Patient selection

Patients with a histologically confirmed solid cancer without curative treatment options were eligible. Inclusion criteria were: WHO performance status 0–2; adequate bone marrow, hepatic and renal function; life expectancy > 3 months and written informed consent. Patients with a recent (<3 months) myocardial infarction, uncontrolled infectious disease, pregnancy, previous administration of cetuximab or concurrent treatment with anti-cancer agents or radiotherapy were excluded.

Study design

A study design with two different dose schedules was used (Fig. 1). In both steps, ⁸⁹Zr-cetuximab was administered within one hour after administration of the loading dose of unlabelled cetuximab. Six patients were included, three in each dose schedule. If in any patient grade 2 or higher toxicity was observed related to ⁸⁹Zr-cetuximab administration, 3 extra patients would be included in this dose step. When at maximum 1/6 patients experienced grade 2 toxicity, the step was considered safe.

The study design anticipated the future aim, which is to determine the tumour uptake of ⁸⁹Zr-cetuximab before and during therapy. Therefore, in the first dose schedule (step 1), toxicity of two consecutive low doses of ⁸⁹Zr-cetuximab was investigated. A standard loading dose of 400 mg/m² cetuximab, followed by 10 mg of ⁸⁹Zr-cetuximab (60 MBq) was administered on day 0. A second injection with a maintenance dose of 250 mg/m² of cetuximab,

followed by 10 mg of ⁸⁹Zr-cetuximab (60 MBq) was administered on day 14.

As a larger radioactivity dose of ⁸⁹Zr-cetuximab is possibly needed to obtain the best image quality, toxicity of a single larger dose was investigated in a second dose schedule (step 2). A loading dose of 400 mg/m² of cetuximab was administered followed by injection of 10 mg of cetuximab labelled with 120 MBq ⁸⁹Zr.

During inclusion in step 2, a study amendment was written based on the first results of the image analysis. It was decided that if the secondary endpoint (assessment of tumour ⁸⁹Zr-cetuximab uptake) could not be satisfactorily assessed based on the first 6 patients, a third step would be added in which 3 patients were included with an EGFR overexpressing tumour based on recent immunohistochemistry. For these patients, the administration schedule was the same as in step 2.

The study protocol was approved by the medical ethical committee and the radiation safety committee. The study is listed in clinicaltrials.gov number NCT00691548.

EGFR expression and mutation status

In all patients, biopsies of the primary tumour were taken before the start of treatment. For patients included in step 3, a recent biopsy of the primary tumour or from a metastatic lesion had to be available, without any antitumour treatment between the biopsy and inclusion. After inclusion, EGFR expression and mutation status (exons 18–21) as well as *KRAS* mutation (codons 12 and 13) were assessed on these biopsies [18]. EGFR expression was analysed with the EGFR pharmDx qualitative immunohistochemical kit system (Novocastra and Dako, Denmark). To quantify EGFR expression, both EGFR membrane staining intensity and the percentage of EGFR expressing cells were taken into account. EGFR membrane staining intensity was expressed as a score between 0 (none) and 3+ (strong). The percentage of cells staining at different intensities was assessed visually. Subsequently, EGFR immunohistochemistry (IHC) scores were defined on a scale of 0–300 using a formula combining percentage of staining cells and staining intensity [19]. Tumours were divided in showing low and high EGFR-expression on basis of a score <200 and ≥200, a threshold based on the results of the FLEX study [20,21].




Fig. 1. Timeline of the study: ⁸⁹Zr-cetuximab injection (grey arrows) and the acquiring of ⁸⁹Zr-cetuximab PET/CT scans (black arrows). In step 2, PET-CT scans on days 3 and 7 after injection were optional and depended on the imaging results in step 1: If in step 1 two or more patients had a higher tumour to blood ratio (TBR) on day 4 than on day 5, an additional scan on day 3 would be performed. If in step 1 two or more patients had a higher TBR on day 6 than on day 5, an additional scan on day 7 would be performed. Patients included in step 3 were scanned at one time point only, based on the imaging results of steps 1 and 2.

Toxicity scoring

Toxicity was assessed during treatment and twice weekly thereafter until 14 days after the last injection, according to the CTCAE 3.0 scoring system. At baseline and on days 7 and 14 after injection, blood testing was performed for haematology, kidney and liver function.

The most common side effect of cetuximab administration that was anticipated for was skin toxicity (acneform rash) [22]. As skin toxicity is a known side effect of unlabelled cetuximab administration and this trial aimed to investigate the safety of labelled cetuximab, skin toxicity was not regarded as a dose limiting side effect.

Synthesis of ^{89}Zr -cetuximab

^{89}Zr was produced by a (p,n) reaction on natural ^{89}Y as described by Verel et al. [23]. Subsequently, labelling of ^{89}Zr to the mAb cetuximab was performed as previously reported [24].

PET-CT imaging

PET-CT imaging was performed at days 4, 5 and 6 after injection in dose step 1. Imaging intervals in step 2 were adapted based on the TBRs at subsequent days in step 1. Patients included in step 3 were scanned at one time point only, based on the imaging results of steps 1 and 2. Furthermore, an optional ^{18}F -fluorodeoxyglucose (FDG-)PET scan was performed within the study period, at least 24 h before or 12 days after ^{89}Zr -cetuximab administration (≥ 4 times the half-life of cetuximab). In the first patient that underwent an FDG-PET scan after the ^{89}Zr -cetuximab administration, an extra PET-CT scan was performed at day 12, preceding FDG-injection, to assess remaining activity associated with the ^{89}Zr -cetuximab administration.

Image analysis

Tumour sites and normal tissues were manually delineated on one of the ^{89}Zr -cetuximab PET-CT scans (day 6 or 7) by the same observer (JvL). For one patient, delineations were performed on the FDG-PET-CT scan. Tumour sites were delineated based on the CT using FDG-PET information when available. To quantify uptake in muscle and liver, a transversal CT slice of the subscapular muscle and the liver was delineated. The resulting regions of interest were subsequently projected onto the other ^{89}Zr -cetuximab-PET-CT scans and FDG-PET scan through co-registration of the corresponding CT images using rigid registration.

The mean, maximum and peak standardized uptake value (SUV_{mean} , SUV_{max} and SUV_{peak} , respectively) were determined using in-house developed dedicated software. The tumour SUV_{peak} was defined by calculating the mean SUV in a sphere with a diameter of 1.2 cm within the tumour region with the highest activity. Tumour to background ratio (TBR) was calculated by dividing tumour SUV_{peak} by SUV_{mean} in the aortic arch.

For patients in whom an additional ^{18}F -FDG-PET scan was performed, the ^{18}F FDG and ^{89}Zr -cetuximab uptake was visually compared.

Results

Patient characteristics are shown in Supplementary Table 1, tumour characteristics in Table 1. Nine patients, with a median age of 62 years (range: 53–75), were included. The third patient was excluded from the study before injection of ^{89}Zr -labelled cetuximab, because of malignant hypertension during administration of the unlabelled cetuximab. The blood pressure normalized within two hours of observation without further

Table 1
Tumour characteristics and tumour and normal tissue uptake.

Primary tumour	Site	Histology	Mutation [*]	EGFR IHC score	Schedule									
					FDG-PET		^{89}Zr -cetuximab PET							
					Tumour		TBRpeak	SUVpeak	SUVmax	SUVmean	Liver		Muscle	
					SUVmax	SUVmin					SUVmax	SUVmean	SUVmax	SUVmean
1	Lung	SCC	NA	NA	11.26	2.78	4.74	4.74	7.05	1.80	NA	NA	3.41	0.59
2	Lung	LCC	k-ras: +	80	-	3.11	4.28	4.28	7.84	2.14	NA	NA	2.62	0.55
3 ^{**}	Lung	LCC	EGFR: -	-	-	-	-	-	-	-	-	-	-	-
4	Lung	AC	k-ras: -	280	-	4.56	3.83	3.83	7.62	1.30	8.11	5.45	1.43	0.37
5	Lung	SCC	EGFR: -	240	10.21	0.96	1.18	1.18	1.62	0.79	7.75	5.68	0.97	0.21
6	Lung	AC	k-ras: -	290	7.58	1.74	3.59	3.59	6.62	1.85	9.92	9.23	1.27	0.32
7	Oropharynx	SCC	EGFR: -	300	11.28	3.20	2.95	2.95	4.32	1.97	6.98	5.26	1.63	0.27
8	Oropharynx	MC	k-ras: -	270	-	1.35	4.35	4.35	6.19	3.15	7.11	6.81	1.78	0.75
9	Oropharynx	SCC	EGFR: -	290	-	1.46	4.77	4.77	6.92	2.95	18.42	12.47	1.24	0.44

SCC: squamous cell carcinoma; LCC: large cell carcinoma; AC: adenocarcinoma; MC: muco-epidermoid carcinoma; NA: not assessable due to insufficient quantity of histological material; TBR: tumour to blood ratio.

^{*} k-ras: codons 12 and 13; EGFR: exons 18–21.

^{**} Excluded patient.




Fig. 2. ⁸⁹Zr-cetuximab PET maximum intensity projections of all patients. The GTV of the primary tumour is overlaid in blue. The notes underneath the images indicate in which dose step the patients were included, how many days post injection the displayed images were acquired and the dose of ⁸⁹Zr-cetuximab (2 × 60 MBq or 1 × 120 MBq) administered. The scans with the highest TBR in the primary tumour were selected. For dose step 1, the images after the first injection were analysed.

consequences. Therefore an extra patient (patient 4) was included in dose step 1. Only 2 patients were included in step 3 of the study. Given the slow accrual, and since this step was not necessary to reach the primary endpoint, it was decided to close this step prematurely.

From the 9 patients included, 6 had non-small cell lung cancer (NSCLC) and 3 had head and neck cancer (HNC). All patients had previously undergone anti-cancer therapy. In one patient, EGFR expression and mutation and *KRAS* mutation status of the primary tumour could not be assessed due to insufficient quantity of histological material. In the other patients, 6 of the 7 primary tumours showed high EGFR expression, while none showed a mutation of the EGFR gene. An example of IHC staining in a biopsy with high EGFR expression is shown in [Supplementary Fig. 1](#) (Patient 6). In the only patient with low EGFR expression, the primary tumour showed a mutation in the *KRAS* gene. One of the two patients included in step 3 showed high EGFR expression on a recent tumour biopsy. The recent specimen of the second patient contained insufficient material to allow a reliable EGFR analysis.

Each patient received ⁸⁹Zr-cetuximab administration as planned. Patients included in steps 1 and 2 underwent the ⁸⁹Zr-PET-CT scans at 3 consecutive days, except for patient 6 who could not undergo the first scan due to pain. Patient 4, included in step 1, was scanned at day 5–7 instead of day 4–6 because of logistical reasons. In two patients (patient 2 and 4)

enrolled in the first dose step, the series of PET-CT scans after the second injection could not be performed due to pain and dyspnoea. Patients included in step 3 were scanned at day 6 after injection. Four patients underwent an FDG-PET scan within the study period, at an interval of 12 or 13 days after the injection of ⁸⁹Zr-cetuximab.

An overview of the toxicity per patient is presented in [Supplementary Table 2](#). No toxicity other than skin rash was observed in any of the patients. Of the eight patients that received the full cetuximab administration, three experienced grade 1, and 4 experienced grade 2 acne form rash. No changes were observed for haematological, kidney and liver function compared to baseline.

⁸⁹Zr-cetuximab-PET images of all patients are shown in [Fig. 2](#) (coronal) and [Fig. 3](#) (transversal). Tumour and normal tissue uptake values of ⁸⁹Zr-cetuximab are shown in [Table 1](#). All but one patient had a peak TBR > 1 at any of the imaging time points. For each patient, the ⁸⁹Zr-cetuximab image with the highest TBR was selected for further analyses. For patient in dose step 1, only the scans after the first ⁸⁹Zr-cetuximab injection were analysed since for two of the three patients PET/CT could not be acquired in the second week. The average peak TBR was 2.39 (range 0.96–4.56). The average tumour SUV_{max} and SUV_{mean} were 6.02 (range: 1.62–7.84) and 1.99 (range 0.79–3.15), respectively. The average SUV_{max} and SUV_{mean} for the liver were 9.71 (range: 6.98–18.42) and 7.48 (range 5.26–12.47). For muscle, the average SUV_{max} and SUV_{mean} were 1.79 (range: 0.97–3.41) and 0.44 (range




Fig. 3. ^{89}Zr -cetuximab PET-CT images at tumour level showing uptake in SUV. The primary tumour is delineated in blue. The scans with the highest TBR in the primary tumour were selected.

0.21–0.75). Both SUV_{max} and SUV_{mean} of the tumour were significantly higher than the muscle SUV_{max} and mean.

The ^{18}F FDG-PET and ^{89}Zr -cetuximab uptake of the four patients who had an FDG-PET-CT scan is shown in Fig. 4. Visual comparison showed a remarkable mismatch between FDG and ^{89}Zr -cetuximab uptake in one patient (patient 1, Fig. 4A).

No direct relationship was observed between the EGFR IHC score and TBR.

For the patients in dose step 1, the average peak TBR at days 4, 5 and 6 after the first injection was 1.33 (range: 1.23–1.43), 2.06 (range: 1.67–2.65) and 3.12 (range: 1.68–4.56), respectively (Fig. 5). As the highest TBR was found at day 6 after injection, imaging in dose step 2 was performed at days 5, 6 and 7. For patients in dose step 2, the average peak TBR at days 5, 6 and 7 after injection was 1.65 (range: 0.94–2.37), 1.64 (range: 0.96–2.71) and 1.96 (range: 0.94–3.20) (Fig. 5). The peak TBR of patients included in step 3 was 1.35 and 1.46 (day 6). At the regular imaging time points, the highest peak TBR was seen in patient 4 (4.56), at day 6 after injection. In patient 1, an extra PET-CT scan was performed at day 12 after injection. The TBR at this time point was higher than the maximum TBR for this patient at the regular imaging time points (2.78 and 1.68, respectively).

Discussion

The current phase I trial is the first study in HNC and NSCLC evaluating the safety of ^{89}Zr -cetuximab. It is a first step towards




Fig. 4. Correlation between ^{89}Zr -cetuximab and ^{18}F FDG uptake for the four patients receiving both scans. PET uptake is shown in SUV. The primary tumour is delineated in blue. The ^{89}Zr -cetuximab scans with the highest TBR in the primary tumour were selected.

a new patient selection method for cetuximab treatment or the addition of cetuximab to radiotherapy. ^{89}Zr -cetuximab has until now only been evaluated in human patients with colorectal cancer [25]. In this study, no additional toxicity was associated with ^{89}Zr -cetuximab administration. Acne form eruption \leq grade 2 was observed in 88% of patients, a rate comparable to that found with therapeutic administration of cetuximab [4,22,26]. One patient developed malignant hypertension during the administration of unlabelled cetuximab. Although rare, this side-effect has been described previously [27].

Tumour uptake of ^{89}Zr -cetuximab

It should be emphasized that no definitive conclusions can be drawn given the small amount of patients as well as the heterogeneity in tumour type and previous anticancer treatment. All but one patient that completed the study protocol showed a peak TBR > 1 . Visually, however, the ^{89}Zr -cetuximab images showed a rather patchy distribution, without an evident specific uptake of ^{89}Zr -cetuximab within the tumour. Visually comparing the ^{89}Zr -cetuximab images of NSCLC and HNC patients, more discernible tumour uptake appeared to be present in at least one of the HNC patients (Fig. 3G).




Fig. 5. ^{89}Zr -cetuximab tumour to blood ratios at different time points after injection of the tracer. The patients displayed with a black line were included in dose step 1; the patients with a grey line in dose step 2; the patients with a single black marker in dose step 3.

No direct relationship was observed between EGFR IHC score and TBR, similar to the findings in our preclinical study [16]. There are several considerations that argue a direct relationship between EGFR expression at a biopsy specimen and response to cetuximab treatment. Firstly as expression of EGFR can be induced by radiation and chemotherapy, it is possible that an initially EGFR negative tumour may become positive early during therapy, thereby still benefiting from cetuximab treatment [28,29]. Secondly, EGFR expressing tumours will not respond to cetuximab when cetuximab does not reach therapeutic concentrations in the tumour because of e.g. interstitial pressure and vascular perfusion changes [30].

Recommended ^{89}Zr -cetuximab dose and time interval for scanning

A large divergence was observed in the time curves of the TBR. Hence, no optimal imaging time point can be derived from these data. However, we advise a time delay of at least 6 days after injection, as 5 of the 6 patients that were scanned at days 5 and 6 showed a higher TBR at day 6. This is in line with a study in colorectal cancer that also found an optimal scanning time point 6 days post injection [25]. In the only patient that was scanned after a substantially longer time interval (12 days after administration), the highest TBR was found at this time point. This late rise in TBR suggests that a later imaging time point might result in more optimal tumour visualization. Due to decay, however, accurate quantification at such late time intervals may be biased by increased noise levels.

Although no definitive conclusions can be drawn regarding the dosage of labelled cetuximab in view of the different tumour characteristics in the two dose schedules, the current results do not indicate that a higher dose would result in more optimal TBRs. Therefore, taking into account the ALARA (as low as reasonably achievable) principle, a dose of 60 MBq of ^{89}Zr -cetuximab is recommended for future study.

Recommendations for further study

There are some other factors of which the influence on tumour visualization should be assessed in future studies. First, the loading dose administered in this study (400 mg/m²), which is the standard therapeutic regimen, might be suboptimal to enable adequate

tumour visualization. A loading dose of cetuximab is required as cetuximab first binds irreversibly to EGFR expressing liver cells, and tumour cells are only targeted after the liver has been saturated. This rationale is supported by animal studies as well as by the positive relation between skin toxicity and tumour response to cetuximab, implying that skin saturation only occurs after the liver has been saturated [31,32]. The liver SUV_{max} and SUV_{mean} in the current trial were rather high, implying that EGF receptors of the liver were still not saturated by the loading dose.

Based on the promising clinical results of adding cetuximab to radiotherapy in head and neck cancer [4], and the imaging data from the current study suggesting specific ^{89}Zr -cetuximab uptake in at least one of the HNC patients, a clinical trial was started in this patient group (e.g. in the ARTFORCE head and neck trial, clinicaltrials.gov: NCT01504815 [33]). Unfortunately, due to slow accrual, complexity of ^{89}Zr -cetuximab imaging for both patients and radiotherapy departments, and discontinuation of the funding of cetuximab, the study was amended and ^{89}Zr -cetuximab imaging and cetuximab treatment were discontinued.

In conclusion, the administration of ^{89}Zr -cetuximab to image *in vivo* cetuximab uptake is safe and not associated with any additional toxicity compared to unlabelled cetuximab. The recommended time interval between cetuximab administration and scanning is at least 6 days. The recommended ^{89}Zr -cetuximab dose is 60 MBq. Further research is needed to explore the optimal loading dose of non-labelled cetuximab and the relationship with EGFR expression.

Conflict of interest statement

The authors declare that there are no conflicts of interest.

Acknowledgements

We acknowledge financial support from the CTMM framework (AIRFORCE), EU 6th and 7th framework program (Euroxy, Metoxia and ARTFORCE), Interreg (www.eurocat.info), Kankeronderzoeksfonds Limburg (Health Foundation Limburg), the National Institute of Health (NIH-USA U01 CA 143062-01) and the Dutch Cancer Society (KWF UM 2008-4210, 2009-4454, 2011-5020 and KWF MAC 2013-6425).

Appendix A. Supplementary data

Supplementary data associated with this article can be found, in the online version, at <http://dx.doi.org/10.1016/j.radonc.2016.11.020>.

References

- [1] Rowinsky EK. The erbB family: targets for therapeutic development against cancer and therapeutic strategies using monoclonal antibodies and tyrosine kinase inhibitors. *Annu Rev Med* 2004;55:433–57.
- [2] Herbst RS. Review of epidermal growth factor receptor biology. *Int J Radiat Oncol Biol Phys* 2004;59:21–6.
- [3] Ang KK, Berkey BA, Tu X, et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. *Cancer Res* 2002;62:7350–6.
- [4] Bonner JA, Harari PM, Giralt J, et al. Radiotherapy plus cetuximab for squamous-cell carcinoma of the head and neck. *N Engl J Med* 2006;354:567–78.
- [5] Petrelli F, Coinu A, Riboldi V, et al. Concomitant platinum-based chemotherapy or cetuximab with radiotherapy for locally advanced head and neck cancer: a systematic review and meta-analysis of published studies. *Oral Oncol* 2014;50:1041–8.
- [6] Ang KK, Zhang Q, Rosenthal DI, et al. Randomized phase III trial of concurrent accelerated radiation plus cisplatin with or without cetuximab for stage III to IV head and neck carcinoma: RTOG 0522. *J Clin Oncol* 2014;32:2940–50.
- [7] Bradley JDMG, Hu C, Blumenschein G. An intergroup randomized phase III comparison of standard dose versus high dose chemoradiotherapy with or without cetuximab for unresectable stage III non-small cell lung cancer: results on cetuximab effect from RTOG 0617. *J Thorac Oncol* 2013;8:S1–S1410.
- [8] Walraven I, van den Heuvel M, van Diessen J, et al. Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab. *Radiother Oncol* 2016;118:442–6.
- [9] Kriegs M, Gurtner K, Can Y, et al. Radiosensitization of NSCLC cells by EGFR inhibition is the result of an enhanced p53-dependent G1 arrest. *Radiother Oncol* 2015;115:120–7.
- [10] Stegeman H, Kaanders JH, van der Kogel AJ, et al. Predictive value of hypoxia, proliferation and tyrosine kinase receptors for EGFR-inhibition and radiotherapy sensitivity in head and neck cancer models. *Radiother Oncol* 2013;106:383–9.
- [11] van Dongen GA, Visser GW, Lub-de Hooge MN, de Vries EG, Perk LR. Immuno-PET: a navigator in monoclonal antibody development and applications. *Oncologist* 2007;12:1379–89.
- [12] Koi L, Bergmann R, Bruchner K, et al. Radiolabeled anti-EGFR-antibody improves local tumor control after external beam radiotherapy and offers therapeutic potential. *Radiother Oncol* 2014;110:362–9.
- [13] van Dijk LK, Hoebe BA, Stegeman H, et al. ¹¹¹In-cetuximab-F(ab')₂ SPECT imaging for quantification of accessible epidermal growth factor receptors (EGFR) in HNSCC xenografts. *Radiother Oncol* 2013;108:484–8.
- [14] Fracasso PM, Burris 3rd H, Arquette MA, et al. A phase 1 escalating single-dose and weekly fixed-dose study of cetuximab: pharmacokinetic and pharmacodynamic rationale for dosing. *Clin Cancer Res* 2007;13:986–93.
- [15] Vosjan MJ, Perk LR, Visser GW, et al. Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine. *Nat Protoc* 2010;5:739–43.
- [16] Aerts HJ, Dubois L, Perk L, et al. Disparity between in vivo EGFR expression and ⁸⁹Zr-labeled cetuximab uptake assessed with PET. *J Nucl Med* 2009;50:123–31.
- [17] Aerts HJ, Dubois L, Hackeng TM, et al. Development and evaluation of a cetuximab-based imaging probe to target EGFR and EGFRvIII. *Radiother Oncol* 2007;83:326–32.
- [18] Heinemann V, Stintzing S, Kirchner T, Boeck S, Jung A. Clinical relevance of EGFR- and KRAS-status in colorectal cancer patients treated with monoclonal antibodies directed against the EGFR. *Cancer Treat Rev* 2009;35:262–71.
- [19] Lee HJ, Xu X, Choe G, et al. Protein overexpression and gene amplification of epidermal growth factor receptor in nonsmall cell lung carcinomas: Comparison of four commercially available antibodies by immunohistochemistry and fluorescence in situ hybridization study. *Lung Cancer* 2010;68:375–82.
- [20] Ruschoff J, Kerr KM, Grote HJ, et al. Reproducibility of immunohistochemical scoring for epidermal growth factor receptor expression in non-small cell lung cancer: round robin test. *Arch Pathol Lab Med* 2013;137:1255–61.
- [21] Pirker R, Pereira JR, von Pawel J, et al. EGFR expression as a predictor of survival for first-line chemotherapy plus cetuximab in patients with advanced non-small-cell lung cancer: analysis of data from the phase 3 FLEX study. *Lancet Oncol* 2012;13:33–42.
- [22] Galimont-Collen AF, Vos LE, Lavrijsen AP, Ouwerkerk J, Gelderblom H. Classification and management of skin, hair, nail and mucosal side-effects of epidermal growth factor receptor (EGFR) inhibitors. *Eur J Cancer* 2007;43:845–51.
- [23] Verel I, Visser GW, Boellaard R, Stigter-van Walsum M, Snow GB, van Dongen GA. ⁸⁹Zr immuno-PET: comprehensive procedures for the production of ⁸⁹Zr-labeled monoclonal antibodies. *J Nucl Med* 2003;44:1271–81.
- [24] Perk LR, Visser GW, Vosjan MJ, et al. (89)Zr as a PET surrogate radioisotope for scouting biodistribution of the therapeutic radiometals (90)Y and (177)Lu in tumor-bearing nude mice after coupling to the internalizing antibody cetuximab. *J Nucl Med* 2005;46:1898–906.
- [25] der Houven Menke-van, van Oordt CW, Gootjes EC, Huisman MC, et al. ⁸⁹Zr-cetuximab PET imaging in patients with advanced colorectal cancer. *Oncotarget* 2015;6:30384–93.
- [26] Gatzemeier U, von Pawel J, Vynnychenko I, et al. First-cycle rash and survival in patients with advanced non-small-cell lung cancer receiving cetuximab in combination with first-line chemotherapy: a subgroup analysis of data from the FLEX phase 3 study. *Lancet Oncol* 2011;12:30–7.
- [27] Iakovlev VV, Pintilie M, Morrison A, Fyles AW, Hill RP, Hedley DW. Effect of distributional heterogeneity on the analysis of tumor hypoxia based on carbonic anhydrase IX. *Lab Invest* 2007;87:1206–17.
- [28] Contessa JN, Reardon DB, Todd D, et al. The inducible expression of dominant-negative epidermal growth factor receptor-CD533 results in radiosensitization of human mammary carcinoma cells. *Clin Cancer Res* 1999;5:405–11.
- [29] Schmidt-Ullrich RK, Contessa JN, Dent P, et al. Molecular mechanisms of radiation-induced accelerated repopulation. *Radiat Oncol Invest* 1999;7:321–30.
- [30] de Bree R, Kuik DJ, Quak JJ, et al. The impact of tumour volume and other characteristics on uptake of radiolabelled monoclonal antibodies in tumour tissue of head and neck cancer patients. *Eur J Nucl Med* 1998;25:1562–5.
- [31] Burtneess B, Goldwasser MA, Flood W, Mattar B, Forastiere AA. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. *J Clin Oncol* 2005;23:8646–54.
- [32] Tolmachev V, Rosik D, Wallberg H, et al. Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR ¹¹¹In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount. *Eur J Nucl Med Mol Imaging* 2010;37:613–22.
- [33] Heukelom J, Hamming O, Bartelink H, et al. Adaptive and innovative Radiation Treatment FOR improving Cancer treatment outcome (ARTFORCE): a randomized controlled phase II trial for individualized treatment of head and neck cancer. *BMC Cancer* 2013;13:84.